DarioHealth Valuation

Is DRIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DRIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DRIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DRIO's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for DRIO?

Other financial metrics that can be useful for relative valuation.

DRIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.6x
Enterprise Value/EBITDA-0.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does DRIO's PS Ratio compare to its peers?

The above table shows the PS ratio for DRIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.1x
ONMD OneMedNet
23.5xn/aUS$24.0m
CRVW CareView Communications
3.3xn/aUS$28.0m
VSEE VSee Health
4.3xn/aUS$24.8m
STRM Streamline Health Solutions
1.4x8.6%US$29.2m
DRIO DarioHealth
1.2x31.1%US$23.7m

Price-To-Sales vs Peers: DRIO is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (8.1x).


Price to Earnings Ratio vs Industry

How does DRIO's PE Ratio compare vs other companies in the US Healthcare Services Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.6%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.6%
n/an/an/a
No more companies

Price-To-Sales vs Industry: DRIO is good value based on its Price-To-Sales Ratio (1.2x) compared to the US Healthcare Services industry average (1.9x).


Price to Sales Ratio vs Fair Ratio

What is DRIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DRIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio1.8x

Price-To-Sales vs Fair Ratio: DRIO is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DRIO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.79
US$3.83
+385.2%
22.2%US$5.00US$3.00n/a3
Sep ’25US$0.81
US$3.83
+373.3%
22.2%US$5.00US$3.00n/a3
Aug ’25US$1.04
US$5.67
+444.9%
30.0%US$8.00US$4.00n/a3
Jul ’25US$1.17
US$5.67
+384.3%
30.0%US$8.00US$4.00n/a3
Jun ’25US$1.43
US$5.67
+296.3%
30.0%US$8.00US$4.00n/a3
May ’25US$1.46
US$5.67
+288.1%
30.0%US$8.00US$4.00n/a3
Apr ’25US$1.48
US$5.67
+282.9%
30.0%US$8.00US$4.00n/a3
Mar ’25US$2.00
US$5.63
+182.0%
26.2%US$8.00US$4.00n/a4
Feb ’25US$1.91
US$4.88
+155.2%
41.3%US$8.00US$2.50n/a4
Jan ’25US$1.72
US$4.70
+173.3%
39.0%US$8.00US$2.50n/a5
Dec ’24US$1.41
US$4.70
+233.3%
39.0%US$8.00US$2.50n/a5
Nov ’24US$1.01
US$7.82
+674.3%
38.0%US$13.00US$4.10n/a5
Oct ’24US$3.28
US$7.82
+138.4%
38.0%US$13.00US$4.10n/a5
Sep ’24US$3.20
US$7.82
+144.4%
38.0%US$13.00US$4.10US$0.815
Aug ’24US$3.68
US$9.36
+154.4%
39.6%US$14.00US$5.45US$1.044
Jul ’24US$4.01
US$10.25
+155.6%
29.6%US$14.00US$6.00US$1.174
Jun ’24US$4.00
US$9.80
+145.0%
29.1%US$14.00US$6.00US$1.435
May ’24US$3.23
US$11.70
+262.2%
24.4%US$14.00US$7.50US$1.465
Apr ’24US$4.12
US$11.70
+184.0%
24.4%US$14.00US$7.50US$1.485
Mar ’24US$4.59
US$12.10
+163.6%
21.3%US$14.00US$7.50US$2.005
Feb ’24US$5.43
US$12.25
+125.6%
19.4%US$14.00US$7.50US$1.916
Jan ’24US$4.28
US$12.25
+186.2%
19.4%US$14.00US$7.50US$1.726
Dec ’23US$4.84
US$12.25
+153.1%
19.4%US$14.00US$7.50US$1.416
Nov ’23US$4.45
US$15.02
+237.6%
40.0%US$29.00US$9.15US$1.017
Oct ’23US$4.63
US$15.02
+224.4%
40.0%US$29.00US$9.15US$3.287
Sep ’23US$4.58
US$15.39
+236.1%
37.0%US$29.00US$9.15US$3.208

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies